MDR (EU) 2017/745
Monitoring of products in the market
The MDR defines Post-Market Surveillance (PMS) as "all activities undertaken by manufacturers, in collaboration with other economic operators, to establish and keep up to date a systematic procedure to proactively collect and evaluate experience with their products placed on the market, made available or put into service, in order to determine whether it is necessary to take the necessary corrective or preventive action without delay"
As economic operators, specialized distributors keep a register of complaints and non-compliant products and keep the manufacturer informed of these monitoring activities.
In order for us as manufacturers to meet the PMS requirements, you as specialist distributors play an important role in monitoring the products on the market.
In particular, trend reporting under Article 88 MDR challenges us to collect data on non-serious incidents or adverse events that, if they increase in frequency, may lead to risks to the health or safety of patients, users or others.Since these events or complaints are not reportable incidents and we usually have no knowledge of the location of our products, obtaining this data is a challenge for which we rely on your support.
For this purpose, we would like to ask you, in the course of the annual maintenance of KayserBetten, to query possible incidents or complaints at the facilities or families.
Please use the following form and send it to us:
Thank you for your support!
Clearance certificate/ Biocompatibility
The declaration of conformity also serves as a clearance certificate, as the MDR requires proof of biocompatibility for all materials that come into direct or indirect contact with patients or users.
MDR, Appendix I, Paragraph10.2:
Devices shall be designed, manufactured and packaged in such a way as to minimize the risks posed by contaminants and residues to patients - taking into account the intended purpose of the device - and to transport, storage and operating personnel. Special attention is paid to tissues exposed to these contaminants and residues, as well as to the duration and frequency of exposure.
Quality and environmental management
Reuse of beds from KayserBetten
KayserBetten beds provided before 26.05.2021 can be used again without restriction after professional "reprocessing" by cleaning, disinfection, as well as testing and restoration of the technical and functional safety.
The so-called "sell-off provision" (Art. 120(4) MDR) is intended to limit the period during which MDD-compliant products that were already placed on the market (for the first time) before 26.05.2021 may be made available, e.g. by a distributor.
After 27 May 2025, these products may no longer be made available/put into service. Such products that are still in the commercial chain on that day - i.e. have not yet been made available to the end user (e.g. institution, family) as a ready-to-use product - are no longer "tradable".
Trade in used products is not covered by the so-called "sell-off" rule (see MDR recital 3 *). This means that once a product has been made available to the end user (e.g. institution, family) as a ready-to-use product, the further making available of this product on the market does not fall under the scope of the MDR.* MDR, Legal Notice, Recital 3: "This Regulation is not intended to harmonise rules concerning the continued making available on the market of medical devices that have already been put into service, for example in connection with the sale of used devices."
Source: Federal Ministry of Health NACI - National Working Group for the Implementation of the EU Regulations on Medical Devices (MDR) and In Vitro Diagnostic Medical Devices (IVDR EU Regulation on In Vitro Diagnostic Medical Devices).
Placing on the market
"the making available on the Union market of a product, other than a device for testing, for the first time;".
Making available on the market
"any supply of a product, other than investigational devices, for distribution, consumption or use on the Union market in the course of a commercial activity, whether in return for payment or free of charge".
Lifetime and spare parts guarantee
The expected service life of care beds is generally stated to be between 2 and 10 years.
Conditions of use and frequency of use can reduce the service life.
Spare part guaranteeWe guarantee the supply of spare parts for the expected service life.
This availability is limited to parts which, according to experience, are subject to wear within the normal service life of KayserBeds. The guarantee of availability does not apply to other parts which exceed the service life of the beds from KayserBetten.
Technical changes also limit the availability period of spare parts, as our products are continuously developed to ensure that they always comply with the current state of the art and legal requirements when they are placed on the market. This results from our quality management and is a common procedure in the manufacture of medical products.
Maintenance and safety control
According to the MPBetreibV §7, operators of care beds are obliged to ensure the safe condition of the medical device over the entire period of use.
The test according to DIN EN 62353 includes the following minimum requirement:
- Visual inspection
- Insulation resistance measurement
- Leakage current measurement
- Functional test
- Overall evaluation
You can download the KayserBetten maintenance protocol below:
Meldeformular Art.88 - Rev.1.0 >> For more info, see Monitoring products on the market
In accordance with MDR Article 10 Paragraph 11, all our products are supplied with an up-to-date operating manual.
If you require additional operating instructions (printed or as a PDF file), please call us or send us an e-mail. For a quick processing we need the corresponding serial number. You will find it on the product label.